Pharmacology of antidepressants - Characteristics of the ideal drug

E. Richelson

Research output: Contribution to journalArticle

231 Citations (Scopus)

Abstract

Objective: To describe the clinical and basic pharmacologic properties of antidepressants and thus define the pharmacologic criteria for the ideal antidepressant. Design: A review of the pharmacologic characteristics of the newer second-generation antidepressants is presented in relationship to those of the older compounds. Material and Methods: Clinical pharmacologic and in vitro data on the synaptic effects of antidepressants (inhibition of synaptosomal uptake and blockade of neurotransmitter receptors) were obtained for the older antidepressants and for the more recently marketed and approved drugs. The group of antidepressants includes six new antidepressants approved for marketing since 1988 and two additional drugs marketed outside the United States as antidepressants but approved for use in the United States for obsessive-compulsive disorder. Thus, 18 antidepressant drugs are discussed. Results: All antidepressants seem to be equally efficacious in treating depression, and no drug seems to work more rapidly than another. Nonetheless, antidepressant drugs differ substantially in pharmacokinetic variables (elimination half-lives); in their effects on the metabolism of other drugs (by inhibiting the cytochrome P450 system); in their potencies for blocking the reuptake of norepinephrine, serotonin, and dopamine; and in their affinities for blocking histamine H1, muscarinic acetylcholine, α1- adrenergic, and dopamine D2 receptors. Most side effects of antidepressants can be explained by their effects on blocking uptake and on blocking neurotransmitter receptors. Conclusion: The newer second-generation antidepressants have distinct pharmacologic advantages in comparison with the tricyclic antidepressants and the older second-generation compounds. These advantages are clearly seen from their synaptic effects, in which most newer second-generation antidepressants are practically devoid of blocking effects at neurotransmitter receptors. Although the newer second-generation antidepressants are much closer to being the ideal antidepressant than are the older compounds, none completely fulfills the criteria for being the ideal drug.

Original languageEnglish (US)
Pages (from-to)1069-1081
Number of pages13
JournalMayo Clinic Proceedings
Volume69
Issue number11
StatePublished - 1994

Fingerprint

Antidepressive Agents
Pharmacology
Pharmaceutical Preparations
Neurotransmitter Receptor
Dopamine D2 Receptors
Tricyclic Antidepressive Agents
Obsessive-Compulsive Disorder
Marketing
Adrenergic Agents
Cytochrome P-450 Enzyme System
Cholinergic Agents
Histamine
Acetylcholine
Dopamine
Serotonin
Norepinephrine
Pharmacokinetics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pharmacology of antidepressants - Characteristics of the ideal drug. / Richelson, E.

In: Mayo Clinic Proceedings, Vol. 69, No. 11, 1994, p. 1069-1081.

Research output: Contribution to journalArticle

Richelson, E. / Pharmacology of antidepressants - Characteristics of the ideal drug. In: Mayo Clinic Proceedings. 1994 ; Vol. 69, No. 11. pp. 1069-1081.
@article{cd8036dabc3941d3b76dae6bd789ce02,
title = "Pharmacology of antidepressants - Characteristics of the ideal drug",
abstract = "Objective: To describe the clinical and basic pharmacologic properties of antidepressants and thus define the pharmacologic criteria for the ideal antidepressant. Design: A review of the pharmacologic characteristics of the newer second-generation antidepressants is presented in relationship to those of the older compounds. Material and Methods: Clinical pharmacologic and in vitro data on the synaptic effects of antidepressants (inhibition of synaptosomal uptake and blockade of neurotransmitter receptors) were obtained for the older antidepressants and for the more recently marketed and approved drugs. The group of antidepressants includes six new antidepressants approved for marketing since 1988 and two additional drugs marketed outside the United States as antidepressants but approved for use in the United States for obsessive-compulsive disorder. Thus, 18 antidepressant drugs are discussed. Results: All antidepressants seem to be equally efficacious in treating depression, and no drug seems to work more rapidly than another. Nonetheless, antidepressant drugs differ substantially in pharmacokinetic variables (elimination half-lives); in their effects on the metabolism of other drugs (by inhibiting the cytochrome P450 system); in their potencies for blocking the reuptake of norepinephrine, serotonin, and dopamine; and in their affinities for blocking histamine H1, muscarinic acetylcholine, α1- adrenergic, and dopamine D2 receptors. Most side effects of antidepressants can be explained by their effects on blocking uptake and on blocking neurotransmitter receptors. Conclusion: The newer second-generation antidepressants have distinct pharmacologic advantages in comparison with the tricyclic antidepressants and the older second-generation compounds. These advantages are clearly seen from their synaptic effects, in which most newer second-generation antidepressants are practically devoid of blocking effects at neurotransmitter receptors. Although the newer second-generation antidepressants are much closer to being the ideal antidepressant than are the older compounds, none completely fulfills the criteria for being the ideal drug.",
author = "E. Richelson",
year = "1994",
language = "English (US)",
volume = "69",
pages = "1069--1081",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "11",

}

TY - JOUR

T1 - Pharmacology of antidepressants - Characteristics of the ideal drug

AU - Richelson, E.

PY - 1994

Y1 - 1994

N2 - Objective: To describe the clinical and basic pharmacologic properties of antidepressants and thus define the pharmacologic criteria for the ideal antidepressant. Design: A review of the pharmacologic characteristics of the newer second-generation antidepressants is presented in relationship to those of the older compounds. Material and Methods: Clinical pharmacologic and in vitro data on the synaptic effects of antidepressants (inhibition of synaptosomal uptake and blockade of neurotransmitter receptors) were obtained for the older antidepressants and for the more recently marketed and approved drugs. The group of antidepressants includes six new antidepressants approved for marketing since 1988 and two additional drugs marketed outside the United States as antidepressants but approved for use in the United States for obsessive-compulsive disorder. Thus, 18 antidepressant drugs are discussed. Results: All antidepressants seem to be equally efficacious in treating depression, and no drug seems to work more rapidly than another. Nonetheless, antidepressant drugs differ substantially in pharmacokinetic variables (elimination half-lives); in their effects on the metabolism of other drugs (by inhibiting the cytochrome P450 system); in their potencies for blocking the reuptake of norepinephrine, serotonin, and dopamine; and in their affinities for blocking histamine H1, muscarinic acetylcholine, α1- adrenergic, and dopamine D2 receptors. Most side effects of antidepressants can be explained by their effects on blocking uptake and on blocking neurotransmitter receptors. Conclusion: The newer second-generation antidepressants have distinct pharmacologic advantages in comparison with the tricyclic antidepressants and the older second-generation compounds. These advantages are clearly seen from their synaptic effects, in which most newer second-generation antidepressants are practically devoid of blocking effects at neurotransmitter receptors. Although the newer second-generation antidepressants are much closer to being the ideal antidepressant than are the older compounds, none completely fulfills the criteria for being the ideal drug.

AB - Objective: To describe the clinical and basic pharmacologic properties of antidepressants and thus define the pharmacologic criteria for the ideal antidepressant. Design: A review of the pharmacologic characteristics of the newer second-generation antidepressants is presented in relationship to those of the older compounds. Material and Methods: Clinical pharmacologic and in vitro data on the synaptic effects of antidepressants (inhibition of synaptosomal uptake and blockade of neurotransmitter receptors) were obtained for the older antidepressants and for the more recently marketed and approved drugs. The group of antidepressants includes six new antidepressants approved for marketing since 1988 and two additional drugs marketed outside the United States as antidepressants but approved for use in the United States for obsessive-compulsive disorder. Thus, 18 antidepressant drugs are discussed. Results: All antidepressants seem to be equally efficacious in treating depression, and no drug seems to work more rapidly than another. Nonetheless, antidepressant drugs differ substantially in pharmacokinetic variables (elimination half-lives); in their effects on the metabolism of other drugs (by inhibiting the cytochrome P450 system); in their potencies for blocking the reuptake of norepinephrine, serotonin, and dopamine; and in their affinities for blocking histamine H1, muscarinic acetylcholine, α1- adrenergic, and dopamine D2 receptors. Most side effects of antidepressants can be explained by their effects on blocking uptake and on blocking neurotransmitter receptors. Conclusion: The newer second-generation antidepressants have distinct pharmacologic advantages in comparison with the tricyclic antidepressants and the older second-generation compounds. These advantages are clearly seen from their synaptic effects, in which most newer second-generation antidepressants are practically devoid of blocking effects at neurotransmitter receptors. Although the newer second-generation antidepressants are much closer to being the ideal antidepressant than are the older compounds, none completely fulfills the criteria for being the ideal drug.

UR - http://www.scopus.com/inward/record.url?scp=0028099484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028099484&partnerID=8YFLogxK

M3 - Article

C2 - 7967761

AN - SCOPUS:0028099484

VL - 69

SP - 1069

EP - 1081

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 11

ER -